Wang T, Zhang LY. Evaluation of oxaliplatin and tigio combination therapy in locally advanced gastric cancer. World J Gastrointest Surg 2024; 16(6): 1709-1716 [DOI: 10.4240/wjgs.v16.i6.1709]
Corresponding Author of This Article
Li-Yun Zhang, MM, Associate Chief Physician, Department of Gastroenterology, Xianyang Hospital, Yan’an University, Wenjin New Town Residential Area, Yingbin Avenue, Weicheng District, Xianyang 712000, Shaanxi Province, China. zhangliyun0301111@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Jun 27, 2024; 16(6): 1709-1716 Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1709
Evaluation of oxaliplatin and tigio combination therapy in locally advanced gastric cancer
Teng Wang, Li-Yun Zhang
Teng Wang, Li-Yun Zhang, Department of Gastroenterology, Xianyang Hospital, Yan’an University, Xianyang 712000, Shaanxi Province, China
Author contributions: Zhang LY designed this study, collected and analyzed the data; Wang T drafted the manuscript and gave final approval of the version to be published; Wang T and Zhang LY took part in this study as endoscopic operators or assistants.
Institutional review board statement: The study was reviewed and approved by the Medical Ethics Committee of Xianyang Hospital, Yan’an University (Approval No. 2023-299).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that there is no competing interest associated with the manuscript.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Yun Zhang, MM, Associate Chief Physician, Department of Gastroenterology, Xianyang Hospital, Yan’an University, Wenjin New Town Residential Area, Yingbin Avenue, Weicheng District, Xianyang 712000, Shaanxi Province, China. zhangliyun0301111@163.com
Received: March 5, 2024 Revised: April 26, 2024 Accepted: May 14, 2024 Published online: June 27, 2024 Processing time: 116 Days and 22.4 Hours
Abstract
BACKGROUND
Locally advanced gastric cancer (LAGC) is a common malignant tumor. In recent years, neoadjuvant chemotherapy has gradually become popular for the treatment of LAGC.
AIM
To investigate the efficacy of oxaliplatin combined with a tigio neoadjuvant chemotherapy regimen vs a conventional chemotherapy regimen for LAGC.
METHODS
Ninety patients with LAGC were selected and randomly divided into control and study groups with 45 patients in each group, according to the numerical table method. The control group was treated with conventional chemotherapy, and the study group was treated with oxaliplatin combined with tigio-neoadjuvant chemotherapy. The primary outcome measures were the clinical objective response rate (ORR) and surgical resection rate (SRR), whereas the secondary outcome measures were safety and Karnofsky Performance Status score.
RESULTS
The ORR in the study group was 80.00%, which was significantly higher than that of the control group (57.78%). In the study group, SRR was 75.56%, which was significantly higher than that of the control group (57.78%). There were 15.56% adverse reactions in the study group and 35.56% in the control group. These differences were statistically significant between the two groups.
CONCLUSION
The combination of oxaliplatin and tigio before surgery as neoadjuvant chemotherapy for patients with LAGC can effectively improve the ORR and SRR and is safe.
Core Tip: This study identified the following highlights. The objective response rate in the study was 80.00%, which was significantly higher than that of the control group (57.78%). In the study group, 75.56% of the tumors were resected, which was significantly higher than that of the control group (57.78%). There were 15.56% adverse reactions in the study group and 35.56% in the control group. These differences were statistically significant between the two groups.
